Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
Hinge Bio to receive $10 million upfront and is eligible to receive…
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:…
Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech
Specializing in enzymes and fermentation, the biotech company will transform the expansion of…
LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
NORWALK, Conn., Sept. 23, 2025 /PRNewswire/ -- Lifespan Vision Ventures is pleased…
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med…
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:…
Tevogen Recognized in BINJEs BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc.…
Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies
Collaboration in Singapore aims to further expand the broad potential of Life…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET | Source: Belite Bio, Inc - 500…